Last edition
News about "Muscle-Invasive Bladder Cancer "
AstraZeneca's Imfinzi Combo Gets US Priority Review for MIBC
AstraZeneca’s Imfinzi and enfortumab vedotin combination has received US FDA Priority Review based on positive Phase 3 VOLGA results in muscle-invasive bladder cancer.
Muscle-Invasive Bladder Cancer | 28/09/2026 | By News Bureau
Merck Gets Positive EU Opinion for Keytruda-Padcev in MIBC
Merck’s Keytruda plus Padcev receives a positive CHMP opinion for perioperative treatment of adults with resectable muscle-invasive bladder cancer, with the EC set to review the recommendation.
Muscle-Invasive Bladder Cancer | 19/09/2026 | By News Bureau
The European Commission has approved Padcev in combination with Keytruda as the first perioperative treatment for cisplatin-ineligible patients with resectable muscle-invasive bladder cancer in Europe.
Muscle-Invasive Bladder Cancer | 25/06/2026 | By News Bureau | 114
AstraZeneca's Imfinzi Combination Therapy Improves Survival Outcomes in Phase 3 Bladder Cancer Trial
AstraZeneca’s phase 3 VOLGA trial demonstrated significant survival benefits with Imfinzi and enfortumab vedotin in muscle-invasive bladder cancer patients who are ineligible for cisplatin-based chemotherapy, marking another positive milestone in the company’s immunotherapy programme.
Muscle-invasive Bladder Cancer | 15/05/2026 | By News Bureau | 141
FDA Grants Priority Review to Astellas and Pfizer's Bladder Cancer Combination Therapy
Astellas and Pfizer’s Padcev-Keytruda combination moves closer to expanded approval, offering a potential new treatment option to reduce recurrence and improve survival in bladder cancer patients.
Muscle-invasive Bladder Cancer | 21/04/2026 | By News Bureau | 177
KEYTRUDA Plus Padcev Improves Survival Outcomes in MIBC
KEYTRUDA plus Padcev significantly improved survival and pathologic complete response rates in cisplatin-eligible patients with muscle-invasive bladder cancer when used before and after surgery.
Muscle-Invasive Bladder Cancer | 18/12/2025 | By News Bureau | 269
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy